JANX- Janux Therapeutics, Inc.

Name: Janux Therapeutics, Inc. Insider Trading Data
Creator: U.S. Securities and Exchange Commission
License: https://www.sec.gov/privacy#accessibility

Janux Therapeutics, Inc. (JANX) has 13 insiders with recent SEC Form 4 filings, including 9 buys and 8 sells. JANX is classified in the Biotechnology industry within the Health Care sector.

Insider Ownership

Role	Insider	Shares	Value	30d
CEO	Campbell David Alan	264.7K	$4.24M	-
Other	Diraimondo Thomas	155.8K	$2.50M	-
Other	McIver Zachariah	101.5K	$1.63M	-
Other	Winter Charles M.	100.1K	$1.60M	-
Other	Meyer Andrew Hollman	83.1K	$1.33M	-

Activity

Buys and sells only

Transactions

10 filings · page 5

Date	Insider	Role	Type	Shares	Price	Value	Chg%	3M	12M
Dec 21, 2021	Thompson Peter A.63	Director	Sell	119,400	$19.00	$2,268,600.00	-4.5%	-19.6%	-36.7%
Dec 21, 2021	Orbimed Advisors LLC66	Director	Sell	119,400	$19.00	$2,268,600.00	-4.5%	-19.6%	-36.7%
Dec 16, 2021	Thompson Peter A.63	Director	Sell	393,300	$19.07	$7,500,231.00	-12.9%	-10.6%	-35.1%
Dec 16, 2021	Orbimed Advisors LLC66	Director	Sell	393,300	$19.07	$7,500,231.00	-12.9%	-10.6%	-35.1%
Jun 15, 2021	Ra Capital Management, L.P.52	Director, 10% Owner	Buy	2,941,176	$17.00	$49,999,992.00	+51.3%	+52.6%	-37.6%
Jun 15, 2021	Bregua Corp	10% Owner	Buy	58,823	$17.00	$999,991.00	+1.6%	+52.6%	-37.6%
Jun 15, 2021	Avalon Ventures Xi, L.P.80	10% Owner	Buy	629,411	$17.00	$10,699,987.00	+16.3%	+52.6%	-37.6%
Jun 15, 2021	Orbimed Advisors LLC66	Director	Buy	705,853	$17.00	$11,999,501.00	+30.2%	+52.6%	-37.6%
Jun 15, 2021	Lichter Jay70	Director, 10% Owner	Buy	629,411	$17.00	$10,699,987.00	+16.3%	+52.6%	-37.6%
Jun 15, 2021	Thompson Peter A.63	Director	Buy	705,853	$17.00	$11,999,501.00	+30.2%	+52.6%	-37.6%

← PrevPage 5Next →

Insider	Role	Shares	Value	Buys	Sells

Date	Ticker	Insider	Role	Type	Shares	Price	Value	Chg%	SEC